Loading...
•
Dec 31, 2021
Cassava Sciences Q4 2021 Earnings Report
Reported financial results for the full year 2021 and provided clinical and business updates.
Key Takeaways
Cassava Sciences reported a net loss for the full year 2021 of $32.4 million, or $0.82 per share, and has $233.4 million of cash on hand. The company initiated two Phase 3 clinical studies with simufilam in the second half of 2021 and is focused on enrolling over 1,700 patients into the Phase 3 clinical program.
Initiated two Phase 3 clinical studies with simufilam in the second half of 2021.
Phase 3 studies are recruiting patients with mild to moderate Alzheimer’s disease.
Over 200 patients have been screened to date for Phase 3 studies.
Balance sheet has $233.4 million of cash.
Forward Guidance
Cassava Sciences expects to use $25 to $35 million in the first half of 2022, depending on patient enrollment rates and the timing of certain legal expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...